source
- Phase 3 trial shows cancer vaccine intismeran autogene cuts recurrence risk by 42% versus KeytrudaAt the European Society for Medical Oncology Congress, a Phase 3 trial of the personalized cancer vaccine intismeran autogene reported a 42% reduction in risk of recurrence or death compared with p…
- Incyte's KRAS G12D inhibitor shows 89% response rate in early pancreatic cancer trialIn a Phase 1 study, Incyte tested its KRAS G12D inhibitor together with standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma carrying the G12D mutation. The combinati…